Stay updated with the latest healthcare market news, including major mergers, stock movers, and policy updates.

Pertussis is one of the top 10 leading causes of death worldwide and remains a concern in the U.S. despite vaccination ...

Johnson & Johnson entered into a definitive agreement to acquire Halda Therapeutics OpCo for $3.05 billion in cash. Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a ...

Want a COVID-19 vaccination this fall? For many Americans, it's not clear how easy it will be to get one. A vial of Moderna ...

Moderna (MRNA) announced program and financial updates at its Analyst Day event. The updates include mRNA pipeline progress and a three-year plan ...

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...

A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S.

A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

The UK is launching a groundbreaking Horizon trial to see if a vaccine can help people with multiple sclerosis by targeting ...

Japanese Prime Minister Sanae Takaichi is facing her first major diplomatic test less than a month into office, after angering China with remarks about Tokyo’s position on the red line ...

A new trial will test whether a jab to protect against a common virus found in almost all people with multiple sclerosis (MS) ...

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64. Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron ...